股东拟“清仓式”减持 昭衍新药回应

Core Viewpoint - The significant drop in the stock price of Zhaoyan New Drug on March 17 was primarily driven by the news of major shareholder Gu Xiaolei and his concerted party Gu Meifang planning a "clearance-style" reduction of their holdings [1] Group 1 - Zhaoyan New Drug's stock price hit the limit down during trading, indicating a severe market reaction [1] - The company's securities department stated that the stock price decline was mainly influenced by the reduction news [1] - The scale of the current reduction exceeded market expectations, leading to a larger-than-anticipated market response [1]